Navigation Links
Essentialis Promotes Aaron Berg to Chief Executive Officer
Date:12/7/2011

SAN DIEGO, Dec. 7, 2011 /PRNewswire/ -- Essentialis, Inc., announced today the promotion of Aaron D. Berg from President and Chief Commercial Officer to Chief Executive Officer (CEO).  Essentialis is focused on the development of a novel medicine for the treatment of cardiovascular and metabolic disease.  Mr. Berg joined Essentialis in January, 2010 bringing proven business development and product commercialization expertise to the Company and its lead compound, DCCR, now in Phase II development for patients with very high triglycerides.  Mr. Berg was also appointed to the Essentialis Board of Directors.

"Aaron Berg has brought to Essentialis expertise and knowledge from senior positions at Schering-Plough and Kos Pharmaceuticals," said Stuart Collinson, Ph.D., Chairman of the Board.  "As we now transition from mid-stage development to the next phase in our evolution, the Board of Directors recognized Aaron's cardiovascular and metabolic disease expertise make him an ideal leader for Essentialis."

About Aaron Berg

With more than 25 years of industry experience, Mr. Berg demonstrated a consistent record of advancement from sales representative to the pharma c-suite. After beginning his pharmaceutical industry career with Bristol-Myers Squibb, Mr. Berg spent 10 years with Schering-Plough, where he worked in numerous positions of increasing responsibility throughout the commercial organization. Mr. Berg was next recruited by GlaxoSmithKline to help build its newly launched diabetes franchise and then sought an entrepreneurial path.

In 2001, he joined then early stage Kos Pharmaceuticals as a marketing director and rose to Vice President, Marketing and Sales. Kos became widely viewed as a tremendous industry success story, and was acquired by Abbott Laboratories in December, 2006 for $3.6 billion.  His commercial expertise in lipid therapy and understanding of the compound DCCR led Essentialis to tap Mr. Berg as president and now CEO.

About DCCR

DCCR, is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglycerides. Essentialis expects to initiate Phase 3 clinical trials in 2012.  DCCR is covered by multiple issued US patents, which provide composition of matter protection until 2028.  Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.

Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases.  For more information visit http://essentialistherapeutics.com/

Contacts:

Kristie Kuhl
kkuhl@makovsky.com
212-508-9642

Or

Aaron Berg
aberg@essentialistherapeutics.com
858-964-5022

 


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Essentialis to Submit SPA for Hypertriglyceridemia
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
5. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
6. Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer
7. Prescription-Drug Plans Use of Specialty Tiers Promotes Inequalities
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
10. American Imaging Management Promotes Affordability and Choice to Health Care Consumers
11. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):